Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

An automated culture-free system for the identification of bloodstream infections direct from blood

Award Number: R44AI186712
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 07/08/2024
PERIOD OF PERFORMANCE END DATE: 06/30/2027

Group Awards By:

View Award Description

An automated culture-free system for the identification of bloodstream infections direct from blood - PROJECT SUMMARY Leading to over 270,000 deaths in the US annually, septicemia is the systemic inflammatory response to a bloodstream infection (BSI). Studies have shown that early detection and the administration of appropriate antimicrobial treatment for BSIs are crucial for proper patient management and lead to improved patient outcomes and reduced hospitalization times. However, the current diagnostic standard of care relies on blood culture, which is not only slow, requiring ~1-3 days to return a positive result, but also demonstrates reduced sensitivity in the presence of antimicrobial treatment. Consequently, there is a substantial demand for innovative diagnostic approaches that eliminate the need for blood culture and deliver faster and more accurate results. To address this unmet need, HelixBind developed RaPID/BSI, a fully automated sample-to-answer test which identifies BSIs directly from blood in four hours, without cultures. Implemented on the RaPID (Resistance and Pathogen IDentification) platform and appropriate for placement throughout the hospital, RaPID/BSI incorporates a broad test menu of 20 bacterial and fungal pathogens and, crucially, is not compromised by prior antimicrobial treatment. Species level detail is provided with single CFUs/ml sensitivity, enabling selection of appropriate antimicrobials. Commercialization of RaPID/BSI will provide timely characterization of BSIs, enabling intervention with targeted antimicrobials. This is expected to result in improved patient outcomes and a reduction in the use of unnecessary antimicrobials, slowing the rise of antimicrobial resistance. Reflecting RaPID/BSI’s significant advantages over exiting diagnostic standards and the potential to markedly improve care and quality of life, the FDA designated RaPID/BSI a Breakthrough Technology. In this proposed Phase II project, HelixBind will complete verification and validation activities necessary to prepare our submission to the FDA for regulatory clearance. This work includes improvements to the external control material to be provided with the system along with completion of analytical and clinical studies, as reviewed with the FDA. Upon successful completion of this project, we will file for regulatory clearance for RaPID/BSI and bring this breakthrough device to market.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $1,027,841 )
2025	2025	HELIXBIND, INC.	1300 MASSACHUSETTS AVE	BOXBOROUGH	MA	01719	MIDDLESEX	USA	Allergy and Infectious Diseases Research	000	2	7/2/2025	NON-COMPETING CONTINUATION	$1,027,841
														Subtotal = $1,027,841

Issue Date FY: 2024 ( Subtotal = $1,000,000 )
2024	2024	HELIXBIND, INC.	1300 MASSACHUSETTS AVE	BOXBOROUGH	MA	01719	MIDDLESEX	USA	Allergy and Infectious Diseases Research	000	1	7/8/2024	NEW	$1,000,000
														Subtotal = $1,000,000

Grand Total All Awards = $2,027,841

Top

All Categories

About

Search

Reports

Data Submission

Award Information

An automated culture-free system for the identification of bloodstream infections direct from blood

Award Number: R44AI186712

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 07/08/2024

PERIOD OF PERFORMANCE END DATE: 06/30/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer